Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Y-39983. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 7/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 1.00 |
| ▸ | CIT | O14578 | 9/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Y-39983 SCHEMBL29431274 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL226556 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL25685649 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29893202 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29816387 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL599801 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL599800 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29666940 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927760 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927761 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-07-25 | — | — | US | claimed |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | claimed |
| US-20200224159-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2020-07-16 | — | — | US | claimed |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | THE DOSHISHA (JP) | 2020-04-23 | — | — | US | claimed |
| EP-3639855-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | The Doshisha (JP) | 2020-04-22 | — | — | EP | claimed |
| US-20200085804-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2020-03-19 | — | — | US | claimed |
| EP-1378247-B1 | VISUAL FUNCTION DISORDER IMPROVING AGENTS | SENJU PHARMA CO (JP) | 2016-08-24 | — | — | EP | claimed |
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| CN-1362884-A | Preventives/remedies for liver diseases | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-08-07 | — | — | CN | claimed |
| CN-1358102-A | Preventives/remedies for angiostenosis | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2002-07-10 | — | — | CN | claimed |
| CN-1351504-A | Prophylactic and therapeutic agent for interstitial pneumonia and pulmonary fibrosis | YOSHITOMI PHARMACEUTICAL (JP) | 2002-05-29 | — | — | CN | claimed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | claimed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | claimed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | claimed |
| CN-1287494-A | Preventive/remedy for glaucoma | SENJI PHARMACEUTICAL CO LTD (JP) | 2001-03-14 | — | — | CN | claimed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | claimed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228421-A1 | COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 517/4885ROCK1 652/4885CIT 3233/4885 |
| US-20200085804-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 422/4885ROCK1 517/4885CIT 2802/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | ROCK2 90/4885ROCK1 186/4885CIT 268/4885 |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CIT 2410/4885 |
| US-20200121652-A1 | COMPOUNDS HAVING CASPASE INHIBITORY ACTIVITY, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS AND FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION OF SAID PHARMACEUTICAL AGENT | TGFB1, CASP3, TGFB2 | ROCK2 2015/4885ROCK1 1167/4885CIT 1381/4885 |
| US-20210330654-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CIT 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.